Drug Trial Radar · NCT00364923
Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Dec 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
115
Actual
Start
Aug 2006
Primary completion
Jan 2009
Study completion Feb 24, 2009
Sponsor
- Lead sponsor
- Acrotech Biopharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 16, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary • Determine the efficacy of pralatrexate with concurrent vitamin B12 and folic acid supplementation when administered to patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) Secondary * Determine the safety of pralatrexate with concurrent vitamin B12 and folic acid supplementation when administered to patients with relapsed or refractory PTCL * Determine the pharmacokinetic (PK) profile of pralatrexate when administered with vitamin B12 and folic acid supplementation
Conditions
- Peripheral T-cell Lymphoma
Interventions
Pralatrexate InjectionDrug
Pralatrexate 30 mg/m2 via IV push over 3-5 minutes for 6 weeks in a 7 week cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response Rate Per Independent Central ReviewTime frame: Response was assessed at 7 weeks (prior to Cycle 2) and then prior to every other even-numbered cycle (every 14 weeks) until disease progression or death for up to 2 years after initial dose
Locations
32 sites in 6 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
University of California at Los Angeles
Los Angeles, California
Yale University School of Medicine
New Haven, Connecticut
Emory University
Atlanta, Georgia
University of Chicago Hospital
Chicago, Illinois
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Tulane Cancer Center
New Orleans, Louisiana
Dana-Farber Cancer Institute
Boston, Massachusetts
Washington University School of Medicine
St Louis, Missouri
Nevada Cancer Institute
Las Vegas, Nevada
The Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey
Memorial Sloan-Kettering Cancer Center
New York, New York
New York Presbyterian Hospital
New York, New York
Columbia University Medical Center
New York, New York
University of Rochester Cancer Center
Rochester, New York
Fox Chase Cancer Center
Philadelphia, Pennsylvania
UT MD Anderson Cancer Center
Houston, Texas
Fred Hutchinson Cancer Research Center
Seattle, Washington
Cliniques Universitaire Saint-Luc
Brussels, Belgium
Cliniques Universitaires UCL
Yvoir, Belgium
British Columbia Cancer Agency
Vancouver, British Columbia, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
CHU Henri Mondor
Créteil, France
CHU DIJON - Hôpital d'enfant
Dijon, France
CHU Nice - Hôpital de l'Archet 1
Nice, France
CHU Nantes - Hôtel Dieu
Paris, France
CHU Saint Louis
Paris, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
CHU Robert Debré
Reims, France
Ospedale Sant'Orsola - Policlinico Sant'Orsola
Bologna, Italy
St. Georges Hospital
London, United Kingdom
The Royal Marsden NHS Foundation Trust
Sutton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.